Publication at Second Faculty of Medicine |
2005
Abstract
The existing guidelines for the treatment of bronchial asthma include regular preventive anti-inflammatory inhalation therapy as prerequisite for controlling asthma. The most effective drugs of this category are currently combinations of a corticosteroid agent with a long-term β 2 -sympathomimetic.
These drugs are newly available in combination inhalers. A worldwide controlled trial testing the fluticasone and salmeterol oral inhaler for efficacy in better control of asthma is presented.